SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mts362 who wrote (849)4/3/2000 7:37:00 PM
From: david james  Read Replies (2) of 1298
 
I am not sure what you call "real". Cell Genesys created a real technology which they sold in the form of ABGX. They get earnings (real cash) on any profit they made from the sale of that technology. The earnings from that sale goes straight to their P/E. And it should.

Suppose the company created such technology every year, and sold it off to the street. If they could make a profit every year doing that, it should be reflected in their earnings. The cash from those earnings is just as real as selling it in terms of licensing fees or individual medicines.

This is not the same as raising cash by selling your stock to the street.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News